Publications
149
Citations
5,997
Est. group size
—
Recurring co-author estimate
Active years
52
Publishing since 1974
Brian Weiss conducts pediatric cancer research focused on high-risk neuroblastoma, a nervous-system tumor affecting children, and neurofibromatosis type 1 (a genetic condition that causes nerve-related tumors). The work spans clinical trials of new drug therapies (including MEK inhibitors, CAR-NKT cell immunotherapies, and radiolabeled treatments), laboratory studies of tumor biology, and analyses of treatment outcomes and disparities.
Publication activity has been steady across the decade with a notable spike in 2023, averaging roughly 11 papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~22 · 0% small-team papers (≤3 authors) · across 32 venues
- Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas
Pediatric Blood & Cancer · 2026
- Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series
Neuro-Oncology Advances · 2026
- Single-cell and spatial omics reveals region-specific plasticity and therapeutic vulnerabilities in metastatic high-risk neuroblastoma
Science Advances · 2026
- The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma
Human Genetics · 2025
- Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study
Transplantation and Cellular Therapy · 2025
- Abstract 5340: Simultaneous targeting of CDK4/6 and BETs is independent of RB status in osteosarcoma
Cancer Research · 2025
- Abstract 7045: Anti-tumor effects following BET inhibition in preclinical models of pediatric and AYA osteosarcoma
Cancer Research · 2025
- Phase I Study of 131 I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Journal of Clinical Oncology · 2025
- Hemodynamics are associated with subsequent lumen remodeling and clinical maturation of hemodialysis arteriovenous fistula
Scientific Reports · 2025
- Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma
JAMA Network Open · 2025
- A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Cancer · 2025
- Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study
Transplantation and Cellular Therapy · 2025
- Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas
Journal of Clinical Oncology · 2025
- Cardiac Dysfunction in Children and Young Adults Treated With MEK Inhibitors
JACC CardioOncology · 2024
- Tailored ECMO for Respiratory Failure: Moving From Off-the-Rack to Bespoke
ASAIO Journal · 2024
- Journal of Clinical Oncology×16
- Neuro-Oncology×10
- Pediatric Blood & Cancer×7
- Transplantation and Cellular Therapy×3
- Cancer Research×3
- Greg Yanik
Medicine · University of Michigan
- Sahiti Chukkapalli
Medicine · University of Michigan
- Sahr Yazdani
Medicine · University of Michigan
- Keri A. Streby
Medicine · The Ohio State University
- Anthony W. Opipari
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile